Dual inhibition of VEGFR2 with ramucirumab and PD-1 with pembrolizumab has shown potential anti-tumor effect in NSCLC by JVDF trial (NCT02443324) (63). This evidence concerns the gene KDR and non-small cell lung carcinoma.